Research
Macro partitioning
Orlistat produces minimal weight loss (2.78-3.16%) and has a high gastrointestinal side effect profile, making it a less effective first-line treatment compared to GLP-1RAs.
Orlistat is an over-the-counter medication that produces minimal weight loss (approx 3%). It has significant gastrointestinal side effects and is considered less effective than prescription options like GLP-1RAs. It is not recommended as a first-line treatment.
GoodRefutesHIGH confidence
Orlistat reduced mean body weight percentage by 2.78% (95% CI: 2.36%–3.20%)... Orlistat provides little meaningful weight loss and a high gastrointestinal side effect profile and should be avoided as a first-line treatment for obesity.
Why this rating
Supported by multiple meta-analyses.
Source
Comparison of GLP-1RAs vs Other Pharmacotherapy for Obesity
Andrew Overholser et al. · Translation The University of Toledo Journal of Medical Sciences · 2025
narrative_reviewCited 1×
Read the paper This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →